Hey Investor, Welcome to Weekly Picks, where each week our analysts handpick their favorite Narratives. Narratives are a game-changing way for investors to make smarter decisions on their stocks. A narrative always has 3 parts: a story, a forecast and a fair value. You can create one yourself in 3 minutes or you can select one from our thriving community. This week’s picks cover: - 🛍️ Why MINISO’s rapid rollout of high-traffic “Super Stores” could supercharge global sales growth.
- 🌍 Why Procter & Gamble’s deeper push into emerging markets secures its next growth leg.
- 🧬 How a decade-long patent moat locks in pricing power and market dominance for Eli Lilly.
|
| |
MINISO's fair value is projected at 26.69 with an anticipated PE ratio shift of 20x |
MINISO’s growth is driven by rapid global store expansion, the rollout of high-revenue “Super Stores,” and strong overseas momentum supported by IP collaborations and new product categories. Margin expansion from higher overseas mix and operating leverage could drive outsized earnings growth, though execution missteps or competitive pressures remain key risks to sustaining its premium valuation. |
|
|
~19% undervalued vs current price |
Based on ~16% p.a. revenue growth for 3 years |
| |
|
💡 Why we like it: This thesis takes a complex global growth story and turns it into a clear, data-rich narrative—balancing optimism about MINISO’s expansion with a sharp awareness of its execution risks. It’s a well-structured, forward-looking piece that makes the retail growth arc feel both credible and compelling. |
|
| Procter & Gamble: A Dividend Giant Facing Slowing Growth |
Procter & Gamble’s steady cash generation, brand strength, and pricing power support modest growth and reliable dividend increases, underpinned by its global diversification and operational efficiency. However, with slowing revenue momentum and limited margin expansion potential, the stock appears fully valued, offering stability rather than significant upside. |
|
|
~21% overvalued vs current price |
Based on ~5% p.a. revenue growth for 5 years | | |
|
💡 Why we like it: User andre_santos delivers a calm, methodical take on a blue-chip stalwart, layering valuation models with clear assumptions and measured realism. It stands out for its disciplined structure and tone, and despite believing the company is overvalued, the author makes a compelling case for opportunity at the right price. Definitely one for the Watchlist! |
|
|
Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions |
Eli Lilly’s growth is driven by its tirzepatide franchise—Mounjaro and Zepbound—which dominate the fast-expanding diabetes and obesity markets, supported by long patent protection and improving insurance coverage. While high valuations and supply constraints pose short-term risks, easing production limits and sustained demand could drive substantial earnings expansion through 2026. |
|
|
~19% undervalued vs current price |
Based on ~20% p.a. revenue growth for 5 years | | |
|
💡 Why we like it: This narrative captures the excitement around Lilly’s GLP-1 dominance with a steady, fact-driven tone, balancing blockbuster growth with candid realism about capacity and competition. It’s a sharp, forward-looking piece that makes a hot sector story feel grounded and credible. |
|
|
What's next?
1. 🔔 Know when to act: Set the narrative valuations as your own fair value to know when to buy, hold or sell the stock.
2. 🤔 Get answers: Ask the author any questions in the comments section. Feel free to like as well to support their work.
3. ✨ Discover more Narratives: There are hundreds of other insightful stock narratives on our Community page.
4. ✍️ Build an audience: Have your narrative seen by millions of investors, simply meet our Featuring criteria to go into the running! |
|
|
| This email is from Simply Wall Street Pty Ltd
Level 5, 320 Pitt St Sydney 2000, NSW, Australia. Simply Wall St has no position in the company(s) mentioned. These narratives are general in nature and explore scenarios and estimates created by the authors. These narratives do not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company’s future performance and are exploratory in the ideas they cover. The fair value estimates are for informational purposes only and do not constitute a recommendation to buy or sell any stock. They do not take into account your objectives or financial situation. Note that the author’s analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this email/website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us. Privacy Policy Terms and Conditions
Don’t want to get Weekly Pick emails? Click here to stop receiving it.
Want to stop receiving emails or want to check which email you are subscribed on? Click here to manage your email subscriptions. | | |
|
|
|
